Successful delivery of the patient with inherited dysfibrinogenemia

Me’lnikov A.P.; Bondartsova T.S.; Rebrova T.V.; Kulikova O.N.

doi:https://doi.org/10.17116/rosakush20222203162

Me’lnikov A.P.

Moscow Regional Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-7426-9040

Bondartsova T.S.

Moscow Regional Research Institute of Obstetrics and Gynecology

Rebrova T.V.

Moscow Regional Research Institute of Obstetrics and Gynecology

Kulikova O.N.

Moscow Regional Research Institute of Obstetrics and Gynecology

Successful delivery of the patient with inherited dysfibrinogenemia

Authors:

Me’lnikov A.P., Bondartsova T.S., Rebrova T.V., Kulikova O.N.

More about the authors

Journal: Russian Bulletin of Obstetrician-Gynecologist. 2022;22(3): 62‑66

DOI: 10.17116/rosakush20222203162

Read: 1967 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Me’lnikov AP, Bondartsova TS, Rebrova TV, Kulikova ON. Successful delivery of the patient with inherited dysfibrinogenemia. Russian Bulletin of Obstetrician-Gynecologist. 2022;22(3):62‑66. (In Russ.)
https://doi.org/10.17116/rosakush20222203162

Подписка 2026 Российский вестник акушера-гинеколога (Russian Bulletin of Obstetrician-Gynecologist)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Early pregnancy loss: the influence of endogenous risk factors. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):50-58

Live birth rates after conservative treatment of atypical hyperplasia and initial endometrial cancer. Russian Journal of Human Reproduction. 2025;(1):78-85

Abstract:

An analysis of the observation of delivery in a patient with congenital dysfibrinogenemia is presented, and the possibilities of modern laboratory techniques, allowing the prevention of bleeding at delivery and the development of postpartum complications, are shown. «Fibrinogen» should be considered as a «gold standard» of prophylactic therapy.

Keywords:

Inherited dysfibrinogenemia

treatment with fresh frozen plasma

rotational thromboelastometria

thrombodynamic investigation

Authors:

Me’lnikov A.P.

Moscow Regional Research Institute of Obstetrics and Gynecology

ORCID: 0000-0002-7426-9040

Bondartsova T.S.

Moscow Regional Research Institute of Obstetrics and Gynecology

Rebrova T.V.

Moscow Regional Research Institute of Obstetrics and Gynecology

Kulikova O.N.

Moscow Regional Research Institute of Obstetrics and Gynecology

Received:

27.01.2022

Accepted:

02.03.2022

Close metadata

References:

Amri Y, Kallel Ch, Becheur M, Dabboubi R, Elloumi M, Belaaj H, Kammoun S, Messaoud T, de Mocrloose Ph, Toumi N El H. Hypodysfibrinogenemia: a novel abnormal fibrinogen associated with bleeding and thrombotic complications. Clin Chim Acta. 2016;460:1:55-62.
Casini F, Neerman-Arbez M, Triens RA, de Moerloose P, Thromb G. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. Haemost. 2015;13:909-919.
Pike GN, Bolton-Maggs PHB. Factor deficiencies in pregnancy. Haemotol Oncol Clin N Am. 2011;25:2:359-378.
Casini A, Blondon M, Lebreton A, Koegel G, Tintillier V, de Maistre E, Gautier Ph, Biron Ch, Neerman-Arbez M, de Moerloose Ph. Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125:43:553-561.
Bouvier S, Chea M, Ripart S, Hanss M, de Mazancourt Ph, Gris JCh. Successful pregnancy under fibrinogen substitution with heparin and aspirin in a woman with dysfibrinogenemia revealed by placenta abruption. Thrombosis and haemostasis. 2018;8;118(11):2006-2008. https://doi.org/10.1055/s-0038-1673615
Casini A, Blondon M, Lebreton A, Koegel G, Tintillier V, de Maistre E, Gantier Ph, Biron Ch, Neerman-Arbez M, de Moerloose Ph. Natural history of patients with congenital dysfibrinogenemia. Am Soc Hematol. 2015;125:3:553-561.
Chitlur M. Challenges in the laboratory analyses of bleeding disorders. Thromb Res. 2012;130:1:1-6.
Spasiano A, Mattelon C, Orso D, Brussa A, Cafagna M, Marangone A, Dogareschi T, Bove T, Giacomello R, Fontana D, Vetrugno Z, Della Rocca Y. Functional fibrinogen (FLEV-TEG) versus the Clauss method in an obstetric population: a comparative study. BMC Anesthesiol. 2019;19:90. https://doi.org/10.1186/s12871-019-0769-8
Wilrels A, Wetterslev G, Miller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor hemostatic treatment versus usual care in adults or children with bleeding (Review). Cochrane Database of Systemic Reviews. 2016; Issue 8:Art №: CD 007871. CD 007871. pub 3. https://doi.org/10.1002/14651858
Le MoerloseP, Casini A, Neerman-Arbez GM. Congenital fibrinogen disorderds: an update. Thromb Haemost. 2013;39:6:585-595.
The obstetric hematology manual. Ed by S. Pavord and B. Hunt. Cambridge University Press. New York. 2010.
Amgelan A, Allen T, Othman M, Ahmadzia GHK. Systematic review of viscoelastic testing (TEG, ROTEM) in obstetrical and recommendations from the womens SSC of the JSTH. Thromb Haemost. 2020;18:1813-1838.
van Gebben M, van Heerde NZ. Global haemostasis assays brom bench to bedside. Thrombosis Ras. 2012;129:681-687.
Zhou J, Xin Y, Ding Q. Thromboelastography predicts risks of obstetric complication occurrence in (hypo) dysfibrinogenemia patients under non pregnant state. Clin Exper Pharmacol Physiol. 2016;43:149-156.
Kuznik BI, Zagorodilya ED, Iozevson SA, Isakova NV. Thrombodynamic method for studying the hemostasis system in women with physiological pregnancy and complicated preeclampsia. Zhurnal akusherstva i zhenskikh boleznei. 2018;67:6:38-44. (In Russ.).
Bornicova Z, Peyvandi F, Allen G, Bernstein J, Manco-Gohnson MGG. Fibrinogen replacement therapy for congenital fibrinogen deficiency. Thromb Haemost. 2011;9:1687-1704.
Лекарственные препараты в России. Справочник Видаль. М.: Астра Фарм Сервис. СМР Medica VIDAL, Russia.